irAEs, immune-related adverse events; PD-1, programmed cell death 1;
PD-L1, programmed cell death ligand 1; CTLA-4, cytotoxic
T-lymphocyte-associated protein 4; eos, eosinophil; EM, erythema
multiforme; BP, bullous pemphigoid; SJS, Stevens-Johnson syndrome.
Table 4. ICI therapy class, rash treatment, impact on immunotherapy, and
therapeutic response according to the rash grade